Sun Pharma Industries to Acquire Ranbaxy in $3.2B Deal

India’s biggest drugmaker by market value, Sun Pharmaceutical Industries has agreed to buy Ranbaxy Laboratories from Japan’s Daiichi Sankyo Co, which holds approximately 63.4% of the outstanding shares of Ranbaxy, in a $3.2 billion all-share deal, creating the world’s fifth-largest generic drug maker. Under terms of the agreed transaction, Ranbaxy shareholders will receive 0.8 of […] View the full post at: Sun Pharma Industries to Acquire Ranbaxy in $3.2B Deal Related posts: Japan’s Shionogi To Acquire Sciele Pharma (SCRX) for $1.42 Billion Pharma Megamergers: Will They Continue? Cisco to Acquire Starent Networks for $2.9 B